ODH, Inc, 508 Carnegie Center Blvd, Ste 300, Princeton, NJ 08540.
Otsuka America Pharmaceutical, Inc, and Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, New Jersey, USA.
J Clin Psychiatry. 2017 Jul;78(7):e803-e812. doi: 10.4088/JCP.16m11252.
BACKGROUND: There is an unmet need to objectively assess adherence problems that are a common cause of unexplained or unexpected suboptimal outcome. A digital medicine system (DMS) has been developed to address this need in patients with serious mental illness. OBJECTIVE: To conduct a quantitative expert consensus survey to (1) assess relative importance of causes of suboptimal outcomes, (2) examine modalities used to assess adherence, (3) provide guidance on when and how to use the DMS in clinical practice once available, and (4) suggest interventions for specific reasons for nonadherence. METHODS: A panel of 58 experts in psychiatry completed a 23-question survey (October 13 through December 23, 2013) and rated their responses on a 9-point Likert scale. A χ² test of score distributions was used to determine consensus (P < .05). RESULTS: The panel rated adherence as the most important factor in suboptimal outcomes and yet the least likely to be assessed accurately. All predefined uses of the DMS received high mean first-line ratings (≥ 7.4). The experts recognized the utility of the DMS in managing adherence problems, identified clinical situations appropriate for DMS, and assessed potential benefits and challenges of this technology. Consensus was reached on first-line interventions for 10 of 11 reasons for nonadherence. CONCLUSIONS: The results provide a guide to clinicians on the evaluation of suboptimal outcomes, when and how to use the DMS, and the most appropriate interventions to address detected adherence problems.
背景:客观评估导致不明原因或意外疗效不佳的依从性问题的需求尚未得到满足。已经开发出一种数字医疗系统(DMS)来满足严重精神疾病患者的这一需求。
目的:进行定量专家共识调查,以(1)评估疗效不佳的原因的相对重要性,(2)检查用于评估依从性的方法,(3)为 DMS 在临床实践中的使用提供指导,以及(4)为特定的不依从原因提出干预措施。
方法:一组 58 名精神病学专家完成了一项 23 个问题的调查(2013 年 10 月 13 日至 12 月 23 日),并在 9 分制量表上对其回答进行评分。 χ²检验评分分布用于确定共识(P<0.05)。
结果:专家组将依从性评为疗效不佳的最重要因素,但也是最不可能准确评估的因素。所有预定义的 DMS 使用均获得了很高的一线评分(≥7.4)。专家们认识到 DMS 在管理依从性问题方面的实用性,确定了适合 DMS 的临床情况,并评估了该技术的潜在益处和挑战。对于 11 个不依从原因中的 10 个,达成了一线干预措施的共识。
结论:结果为临床医生提供了关于评估疗效不佳、何时以及如何使用 DMS 以及解决检测到的依从性问题的最合适干预措施的指南。
J Clin Psychiatry. 2004
Am J Health Syst Pharm. 2001-10-1
Postgrad Med. 2001-5
Pharmacy (Basel). 2020-6-16